Review Article

To Live or to Die: Prosurvival Activity of PPARγ in Cancers

Y. Lynn Wang and Qi Miao

Molecular Hematopathology Laboratory, Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY 10065, USA

Correspondence should be addressed to Y. Lynn Wang, lyw2001@med.cornell.edu

Received 9 March 2008; Accepted 3 May 2008

Recommended by Dipak Panigrahy

The role of PPARγ in tumorigenesis is controversial. In this article, we review and analyze literature from the past decade that highlights the potential proneoplastic activity of PPARγ. We discuss the following five aspects of the nuclear hormone receptor and its agonists: (1) relative expression of PPARγ in human tumor versus normal tissues; (2) receptor-dependent proneoplastic effects; (3) impact of PPARγ and its agonists on tumors in animal models; (4) clinical trials of thiazolidinediones (TZDs) in human malignancies; (5) TZDs as chemopreventive agents in epidemiology studies. The focus is placed on the most relevant in vivo animal models and human data.

In vitro cell line studies are included only when the effects are shown to be dependent on the PPARγ receptor.

Copyright © 2008 Y. Lynn Wang and Q. Miao. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. INTRODUCTION

PPARγ is a nuclear hormone receptor that requires ligand binding for activation. In 1995, it was discovered that PPARγ is the molecular target of thiazolidinediones (TZDs, [1]), a class of synthetic compounds that are effective for the treatment of type 2 diabetes. This discovery spurred great interest in these agents, as well as in the receptor. Besides its function as an insulin sensitizer in diabetes, PPARγ was found to have a variety of roles in immunoregulation, atherosclerosis, angiogenesis, and tumorigenesis.

With regards to carcinogenesis, debate continues as to whether PPARγ is pro- or antineoplastic, despite very active research over the past few years. At the cellular level, PPARγ was found to be involved in cancer cell survival/apoptosis, proliferation, and differentiation. While the apoptotic functions of PPARγ and its agonists are addressed by others in this special issue, we will conduct a critical review of the literature that suggests that PPARγ has a prosurvival activity. The review is mainly focused on data derived from in vivo models and/or human studies. In vitro cell line-based studies are included only when the effects are shown to be dependent on the PPARγ receptor.

One important lesson learned from the past several years of research is that effects observed with agonists of PPARγ are not necessarily intrinsic effects of the nuclear hormone receptor. In tumor cell survival, the proapoptotic activities of PPARγ agonists in various tumors act through both receptor-dependent and receptor-independent mechanisms. When reviewing the literature, we advise that the readers carefully consider the following to distinguish drugs or TZDs versus receptor effects: (1) are high or low doses used in the studies? High or low doses should be defined with respect to EC50 of glitazones in the PPARγ transactivation assays (Table 1) or plasma concentrations that can be reached in humans (Table 2). Effects observed with high concentrations may not be relevant due to toxicities of certain TZDs, such as hepatotoxicity of troglitazone and potential cardiotoxicity of rosiglitazone (see below). (2) Are multiple pharmacological agents used? If a pharmacological approach is the only one used, claims of a receptor-dependent effect require demonstration with agonists of different chemical structures, such as TZDs, tyrosine analogues, 15-Deoxy-Δ12,14-PGJ2 (15d-PGJ2), and so forth. Beware that 15d-PGJ2 possesses many PPARγ-independent activities, including inhibition of the NFκB pathway, that are known to have prosurvival and anti-inflammatory properties, as well as other effects [2–4]. (3) Are any antagonists included in the study? Do antagonists GW9662 or T0070907 block or reverse the observed effects? (4) Are there any experiments in the study utilizing a genetic
approach to confirm the pharmacological findings? Does the study involve cell lines or primary cells that contain or lack PPARγ, preferably in the same genetic background? For those cell lines with endogenous PPARγ, is the siRNA, shRNA or dominant negative form of PPARγ used to reduce the levels of the receptor? Are specific effects of the receptor diminished by such reduction? For readers’ convenience, these questions are summarized in Table 3.

2. EXPRESSION OF PPARγ IN HUMAN TUMOR VERSUS NORMAL TISSUES

It is generally believed that expression of a gene in a particular tissue suggests that the activity of the encoded protein is required for certain cellular functions of that tissue. In so far as cancers are concerned, the general rule is that oncogenes are overexpressed due to dysregulation, and tumor suppressor genes are underexpressed or absent due to mutations or deletions. In order to clarify the roles of the PPARγ receptor, it would be informative to review the expression levels of PPARγ in tumors with respect to their normal tissue counterparts. In this article, expression data from tumor cell lines are not included.

A review of the current literature on human cancers showed that expression levels of PPARγ mRNA and protein are generally higher in neoplastic tissues than their normal counterparts (summarized in Table 4). The most convincing data came from a large study of prostate cancer that included 156 patients with prostate cancer (PC), 15 with less aggressive prostatic intraepithelial neoplasia (PIN), 20 with benign prostatic hyperplasia, and 12 normal prostate tissues. In this study, a high level of PPARγ expression, by immunohistochemistry, is observed in PC and PIN cases in comparison to low or no expression in the benign hyperplasia and normal tissues. The results were confirmed at the mRNA level with RT-PCR on a few cases from each category of the malignant and benign conditions [13]. A large study of 126 renal cell carcinomas also showed significantly more extensive and intensive PPARγ staining in tumor epithelium compared to the average staining levels seen in 20 normal tissues [14]. Similarly, in 22 patients with nonsmall cell lung carcinoma, higher levels of PPARγ are expressed in tumor cells than in the surrounding normal tissue, as determined by immunohistochemical staining. In addition, higher expression levels in tumor cells are confirmed by Western blotting hybridization, using homogenized tissue samples [15]. In hepatocellular carcinoma, immunostaining also demonstrates that PPARγ is overexpressed in all of 20 carcinoma tissues but not in normal hepatocytes [16]. For squamous cell carcinoma, 20 cases of primary tumor and six cases of lymph node metastasis were demonstrated to have increased PPARγ protein expression compared to normal tongue tissue [17]. Infiltrating adenocarcinoma of the breast also expresses higher nuclear staining of PPARγ compared to normal ductal epithelial cells by immunohistochemical analysis. However, only one of the three cases was shown [18]. For papillary thyroid carcinoma, six patients were studied to determine PPARγ mRNA expression using reverse transcription PCR. The message was found in three of six tumor tissues while the corresponding normal tissues do not express PPARγ [19].

Follicular thyroid carcinoma, a less common histological subtype of thyroid cancer, is characterized by a chromosomal translocation t(2;3) that results in a fusion between paired box gene 8 on chromosome 2 and PPARγ on chromosome 3 (PAX8-PPARγ). The fusion protein was initially thought to function as a dominant-negative inhibitor of the wild-type PPARγ protein [28]. However, a recent microarray study revealed that (1) PPARγ transcript levels in all seven cases of PAX8-PPARγ-containing follicular carcinomas are more than 10-fold higher than normal thyroid tissues, as determined by both microarray and quantitative RT-PCR analyses; (2) the expression profile of the fusion-positive follicular carcinomas shows induction of genes that are involved in fatty acid, amino acid, and glucose metabolic pathways. Interestingly, many of the upregulated genes are known transcriptional targets of the wild-type receptor, suggesting that the PAX8-PPARγ fusion protein functions similarly to wild-type PPARγ, rather than antagonizing its activity. (3) Using cell lines transfected with PPARγ or the fusion protein, it is shown that expression of some genes, including angiogenic factors PIGF and ANGPTL4, is specifically upregulated by the fusion protein, particularly in the absence of ligand, indicating that the fusion protein is constitutively active. Taken together, these experimental data suggest that the translocation enhances the function of PPARγ in a way that contributes to the development or progression of follicular carcinoma of the thyroid [29].

Upregulation of PPARγ has been demonstrated during tumor progression. Mueller et al. have found significant PPARγ staining in six cases of metastatic breast adenocarcinoma. In cell lines established from the primary and metastatic tumors of one of these patients, significantly higher amounts of PPARγ transcript are shown in the cell line derived from the metastatic tumor [20]. In ovarian cancer, intensity and location of PPARγ immunostaining were examined in 28 carcinoma cases along with 28 normal, benign or borderline cases. Twenty six of 28 carcinomas showed strongly positive PPARγ staining compared to 2 weak-staining cases in the control group. Moreover, it is noted that PPARγ staining was predominantly nuclear in grade 2 or 3 tumors, as compared to a predominantly cytoplasmic staining pattern in grade 1 tumors [21]. Similar findings were made in transitional cell carcinoma of urinary bladder. Whereas no significant PPARγ immunoreactivity was observed in 20 normal tissues, elevated PPARγ was found in 168 tumors. Furthermore, the intensity of staining increased as the histological grade increased from G1 to G3 and the tumor stage increased from early (pT1 or lower) to advanced (stage 2 or higher) [22].

A recent large study of 129 cases of pancreatic ductal adenocarcinoma convincingly showed by array-based gene profiling that expression of PPARγ in the tumor cells is ~7 fold higher than that in the normal ductal epithelia. This finding was confirmed with immunohistochemical analysis of the tissue sections. Normal ductal epithelia showed insignificant staining for PPARγ. An early lesion, intraepithelial neoplasia showed occasional PPARγ expression whereas more than
Table 1: EC\textsubscript{50} of common PPARγ agonists in transactivation assays.

| Agonists | Constructs used for transactivation | EC\textsubscript{50} (\mu M) | References |
|----------|------------------------------------|-----------------------------|------------|
| Ciglitazone | mPPARγ\textsubscript{1} LBD-GAL4 DBD\textsuperscript{(b)} | 3 | [5] |
| Pioglitazone | Wild-type mPPARγ\textsubscript{1} | 0.4 | [1] |
| | Wild-type mPPARγ\textsubscript{2} | 0.4 | |
| | mPPARγ\textsubscript{1} \textsuperscript{(c)} LBD-GAL4 DBD | 0.55 | [6] |
| | hPPARγ\textsubscript{1} \textsuperscript{(d)} LBD-GAL4 DBD | 0.58 | |
| Rosiglitazone | Wild-type mPPARγ\textsubscript{1} | 0.03 | [1] |
| | Wild-type mPPARγ\textsubscript{2} | 0.1 | |
| | mPPARγ\textsubscript{1} LBD-GAL4 DBD | 0.076 | [6] |
| | hPPARγ\textsubscript{1} LBD-GAL4 DBD | 0.043 | |
| Troglitazone | mPPARγ\textsubscript{1} LBD-GAL4 DBD | 0.78 | [6] |
| | hPPARγ\textsubscript{1} LBD-GAL4 DBD | 0.55 | |
| 15d-PGJ\textsubscript{2} | Wild-type mPPARγ\textsubscript{1} | 2 | [7] |

(a) LBD, ligand binding domain.
(b) DBD, DNA binding domain.
(c) mPPARγ\textsubscript{1}, mouse PPARγ\textsubscript{1}.
(d) hPPARγ\textsubscript{1}, human PPARγ\textsubscript{1}.

Table 2: Peak plasma concentrations of PPARγ agonists.

| Agonists | C\textsubscript{max} \textsuperscript{(a)} (\mu M) | References |
|----------|-----------------------------------------|------------|
| Ciglitazone | 15–30\textsuperscript{(b)} | [8] |
| Pioglitazone | 0.2–2.5 | [9] |
| Rosiglitazone | 0.2–1.7 | Avandia Prescribing Information\textsuperscript{(c)} |
| Troglitazone | 0.7–8.8 | [10] |
| 15d-PGJ\textsubscript{2} | Low nanomolar to picomolar range\textsuperscript{(d)} | [11] |

(a)\textsuperscript{max}, the maximum or peak plasma concentration in human unless otherwise indicated.
(b) That in dog plasma.
(c) From http://us.gsk.com/products/assets/us_avandia.pdf.
(d) Physiological concentrations in cerebrospinal fluid, urine, and the interior of adipocytes.

Table 3: Points to be considered to discern drugs/TZDs versus receptor effects.

- (1) Are high or low doses of drugs used in the studies with respect to their K\textsubscript{d} values for PPARγ, or plasma concentrations?
- (2) Are multiple pharmacological agents of different chemical classes used?
- (3) Are any antagonists included in the study?
- (4) Are any genetic approaches used to confirm the pharmacological findings?

70% of invasive pancreatic carcinoma demonstrated weak to strong expression. Statistical analysis indeed revealed that expression of PPARγ correlates with high tumor stage and higher tumor histological grade. More strikingly, expression of PPARγ in pancreatic cancer is shown, by multivariant survival analysis, to be a significant prognostic indicator for shortened patient survival [23].

In parallel to the above literature, levels of PPARγ mRNA found in several well- or poorly-differentiated colorectal adenocarcinomas, were similar to normal tissues [24]. Another group also found that the PPARγ immunostaining in well-, moderately-, or poorly-differentiated gastric adenocarcinomas is comparable to that in n Canoncercous tissue adjacent to the tumor [25]. In liposarcomas, PPARγ transcript levels are similar to that of the adipose tissue [26]. In adrenal glands, there is, again, no significant difference in mRNA expression among cases of carcinoma, adenoma, and normal tissues [27]. Notably, at the time of composition of this manuscript, we have not yet found any reports stating that PPARγ expression is downregulated or absent in human tumor versus normal tissues (Table 4).

The next question is whether or not the PPARγ expressed in tumor tissues is functional. Are ligands of PPARγ present in the tumor tissues? A thorough and up to date literature search yielded few results. The English abstract of a study published in a foreign language stated that there was no significant difference in 15d-PGJ\textsubscript{2} concentration between gastric cancer tissues and controls [30]. An earlier study showed that 15d-PGJ\textsubscript{2} promotes the proliferation of HCA-7, a cyclooxygenase 2 (COX-2)-containing colon cancer cell line at nanomolar concentrations. Further characterization by HPLC and mass spectrometry identified PGJ\textsubscript{2}, a chemical precursor of 15d-PGJ\textsubscript{2} in the culture medium of HCA-7 cells [31]. COX-2 is a key enzyme in the biochemical pathway that leads to the formation of cyclopentenone prostaglandins including 15d-PGJ\textsubscript{2}. Overexpression of COX-2 has been documented in many cancer types and contributes to tumor growth [32]. Overall, these few and somewhat circumstantial evidences suggest that 15d-PGJ\textsubscript{2} might be present in the tumor tissues.
Table 4: PPARγ expression in human tumor versus normal tissues.

| Tumor versus normal tissue                                      | No. of cases | References |
|-----------------------------------------------------------------|--------------|------------|
| **Overexpression**                                              |              |            |
| Prostate cancer/prostatic intraepithelial neoplasia              | 156/15       | [13]       |
| Renal cell carcinoma                                             | 126          | [14]       |
| Nonsmall-cell lung carcinoma                                     | 22           | [15]       |
| Hepatocellular carcinoma/lymph node metastasis                  | 20/6         | [16]       |
| Squamous cell carcinoma                                          | 20           | [17]       |
| Metastatic breast adenocarcinoma                                | 6            | [20]       |
| Infiltrating ductal breast adenocarcinoma                       | 3            | [18]       |
| Papillary thyroid carcinoma                                      | 6(a)         | [19]       |
| **Increased expression during tumor progression**                |              |            |
| Breast adenocarcinoma                                           | 1(b)         | [20]       |
| Ovarian carcinoma                                                | 28 versus 28(c) | [21]     |
| Urinary bladder carcinoma                                        | 100 versus 70(d) | [22]  |
| Pancreatic ductal adenocarcinoma                                | 45 versus 84(e) | [23]  |
| **Similar expression**                                          |              |            |
| Colorectal adenocarcinoma                                        | 11           | [24]       |
| Gastric adenocarcinoma                                           | 12           | [25]       |
| Liposarcoma                                                      | 13           | [26]       |
| Adenocortical tumors                                            | 32           | [27]       |

(a) Of the six papillary carcinoma tissues, three expressed PPARγ mRNA.
(b) The primary and metastatic breast cancer cell lines were derived from a single patient.
(c) Normal, benign, or borderline versus malignant tumors (grades 1, 2, and 3).
(d) Lower (≤pT1) versus higher (≥pT2) tumor stages.
(e) Lower (pT1 & pT2) versus higher (pT3 & pT4) tumor stages.

Does PPARγ lose or gain abnormal functions through mutations other than PAX8-PPARγ translocation? A large survey of human tumor samples and cancer cell lines does not support such a notion. The exon 3 and 5 mutations, once reported in sporadic colon cancers [33], were not present in nearly 400 cell lines and primary tumor samples including lung, breast, prostate, colon cancers, and leukemias [34].

Taken together, several lines of evidence regarding PPARγ expression suggest a positive contributive role of the receptor in the development, maintenance, or progression of human malignancies: (1) PPARγ is overexpressed in the vast majority of cancers. (2) In several types of cancer, PPARγ expression is further increased during tumor progression. (3) The oncogenic fusion PAX8-PPARγ results in PPARγ overexpression and upregulation of a similar profile of transcriptional targets as the wild-type protein. (4) Expression of PPARγ in pancreatic cancer is associated with shorter survival.

3. RECEPTOR-DEPENDENT PRONEOPLASTIC EFFECTS OF PPARγ

Is there also cellular-level evidence suggesting that PPARγ promotes tumors? Most studies, especially those employing high doses of TZDs, suggest that PPARγ agonists have anti-tumor activities through inhibition of cell proliferation or induction of apoptosis or differentiation. However, receptor-independent pathways are involved in most of the cases (reviewed elsewhere in this special issue). Then what does the receptor by itself do in tumors?

Schaefer et al. showed that inhibition of PPARγ induces apoptosis of hepatocellular carcinoma cells (HCCs) by preventing their adhesion to the extracellular matrix, suggesting that the activity of PPARγ is required for HCC cells to adhere and survive [16]. In that study, those particular effects were shown to be receptor-dependent. Loss of cell adhesion requires almost complete loss of PPARγ activity achieved by either PPARγ-targeting siRNA or PPARγ inhibitor T0070907. In addition, T0070907 causes cell death at concentrations far lower than those needed for PPARγ agonists rosiglitazone and troglitazone. Together, the data suggest that PPARγ functions to promote tumor cell adhesion and survival in HCC cells. In line with this notion, the promoter region of hepatocyte growth factor contains a functional PPAR response element (PPRE) that mediates its transcriptional upregulation by PPARγ. The growth factor plays an essential role in liver growth during embryonic development, as well as in maintenance and renewal of cells in various organs including liver, lung, and kidney, in adulthood [35].

Our laboratory studied human anaplastic large T-cell lymphomas, a common form of large cell lymphoma in the pediatric population. We first demonstrated with immunohistochemical staining that PPARγ is expressed in the malignant cells of the lymphoma tissues [36]. We then tested the effect of PPARγ activation in cell lines established from patients with this lymphoma. A pair of cell lines,
Karpas 299 and SUP-M2 that, respectively, contain and lack endogenous PPARγ were selected to address the receptor-dependency issue. Additionally, only low ligand concentrations were used, following initial dose titration, to minimize any off-target effects. Using this system, we have found that low doses of PPARγ agonists do not affect cell survival under normal conditions. When cell death was induced by nutrient deprivation through serum withdrawal, activation of the receptor with low doses of rosiglitazone (0.5–2 μM) attenuated cell death, as compared to drug vehicle-treated cells. This result was reproducible with low doses of GW7845 (0.5–2 μM) and 15d-PGJ2 (0.5–1 μM). The effect occurred only in PPARγ-containing Karpas 299 cells but not in PPARγ-lacking SUP-M2 cells. Moreover, reducing PPARγ in Karpas 299 cells with siRNA diminished the prosurvival effect of the receptor. Furthermore, we showed that the prosurvival effect is mediated through PPARγ-dependent cellular metabolic changes, including increased cellular ATP levels, stabilized mitochondrial membrane potential, and reduced reactive oxygen species (ROS) production that each favor cell survival. PPARγ does so through coordinated regulation of the expression of ROS metabolic enzymes, including the p67 subunit of NADPH oxidase, uncoupling protein 2 (UCP2), and manganese superoxide dismutase (Mn-SOD) at both mRNA and protein levels that lead to ROS limitation. Lastly, we showed that stable transfection of PPARγ into SUP-M2 cells not only improved cell survival, but also suppressed ROS accumulation during serum starvation. These genetic manipulations have provided definitive evidence that PPARγ promotes lymphoma cell survival under conditions of nutrient deprivation.

Our group has also made similar findings in a murine cellular model [37, 38]. FL5.12 is a murine lymphocytic cell line that requires interleukin-3 (IL-3) for survival and proliferation. This cell line has been extensively used to characterize tumor cell metabolism [39]. FL5.12 cells express little PPARγ, but are killed by high concentrations of PPARγ agonists, 15d-PGJ2 (≥10 μM) and ciglitazone (≥80 μM). In an FL5.12 cell line stably-transfected with PPARγ, low doses of PPARγ agonist do not affect cell viability under normal conditions. However, when cells are induced to die by IL-3 withdrawal, low doses of ciglitazone (10 μM) and rosiglitazone (0.05–2 μM) improved survival in only PPARγ-containing cells. Improved cell survival is also accompanied by stabilized mitochondria and reduced ROS. Moreover, ATP production is required for PPARγ to exert its prosurvival effect. In this system, expression of a different panel of ROS metabolic enzymes including catalase, and Cu/Zn-SOD are involved in reduction of the cellular levels of ROS. Functional PPRE sequences were shown to be present in the promoter regions of these two genes, suggesting that the upregulation of their expression could be directly regulated by PPARγ [40–42]. Taken together, data from both human and murine cell line studies suggest that PPARγ promotes
tumor cell survival under conditions of nutrient/growth factor deprivation, and that the effect of PPARγ increases cell survival is diagrammed in Figure 1 (Also see below).

In support of the prosurvival activity of PPARγ in T-cell malignancies, Ferreira-Silva et al. very recently showed that RNAi-mediated silencing of PPARγ in Jurkat T-cells caused increased DNA fragmentation and apoptosis as well as G2/M cell cycle arrest, arguing that the receptor, proper, promotes the viability of the tumor cells [43].

In parallel to these findings in tumors, the prosurvival activity of PPARγ has been well documented in certain nonneoplastic pathological conditions, especially ischemia-reperfusion injury in nutrient-sensitive tissues such as brain, heart and kidney [44–51]. Irreversible damage that results from prolonged ischemia causes stroke, and myocardial and kidney infarction. At the cellular level, cell death occurs as a result of nutrient deprivation and inflammatory responses that involve the actions of proinflammatory cytokines, chemokines and transcriptional factors. In addition, increased production of ROS plays an important role in causing damage to macromolecules and eventual cell death [52]. A recent study using a rat model of cerebral focal ischemia has shown that expression of PPARγ mRNA and protein is upregulated in the areas adjacent to infarct caused by middle cerebral artery occlusion [46]. Administration of glitazones prior to, at the time of, or shortly after ischemia induction causes an increase in DNA binding of the receptor. This is accompanied by a decrease in the expression of a number of inflammatory genes, along with an increase in the expression of antioxidant enzymes including catalase and Cu/Zn-SOD [44–47]. Consequently, these changes lead to limited cell demise, which eventually results in significantly reduced infarct size. This process apparently works through a PPARγ-dependent mechanism, as GW9662 can block these effects of TZDs in animals [47]. Another PPARγ antagonist, T0070907, even increases the infarction size, both in the presence and absence of PPARγ ligands [46].

In light of both these findings and the overexpression of PPARγ in many cancers, it is reasonable to hypothesize that the function of PPARγ in cancer is to confer a survival advantage upon the malignant cells, allowing them to survive in an adverse environment. As a result of fast growth, the center of a three dimensional tumor mass is often deprived of oxygen, growth factors, glucose, and other nutrients due to excessive demand and insufficient vasularization. However, cancer cells possess remarkable tolerance and are able to survive despite the adverse conditions [53, 54]. Besides increasing angiogenesis, increasing PPARγ might be another mechanism that allows tumor cells to enhance their survival under these unfavorable conditions (Figure 1).

4. IMPACT OF PPARγ AND ITS AGONISTS ON ANIMAL TUMOR MODELS

Animal models were employed to examine the role of PPARγ in tumors. These systems can be categorized by how the tumor models are generated and by how the dose/activity of PPARγ is altered. With respect to the former, tumors can be generated with xenografts, carcinogens, or genetic manipulations. Watch for spontaneous tumor formation in certain PPARγ genetic backgrounds has also been conducted. With respect to the dose/activity of PPARγ, it can be altered using PPARγ agonists including TZDs or GW7845, or genetic manipulations including hemizygosity or tissue-specific overexpression or deletion of PPARγ. Results differ drastically between different model systems, even for the same types of cancer (Tables 5 and 6). This review focuses on models that are more relevant to human cancers. As such, animal studies involving TZD treatment of xenografted tumors are not discussed here.

4.1. Colon cancer

Apc+/Min mice possess a nonsense mutation in one copy of the adenomatous polyposis coli (APC) gene which truncates the protein at amino acid 850. Loss-of-function mutations in the APC gene are common in human familial adenomatous polyposis and can be found in sporadic colon cancers as well. Using this model, which is highly relevant to human colon cancers, one study showed an increase in tumor number and size, as well as worse histological grade in mice treated with troglitazone or rosiglitazone. This is associated with a rosiglitazone-induced increase in the β-catenin protein level in the colon tissues [55]. Another study [56], which also used Apc+/Min mice, reported an increase in the number of colon polyps in troglitazone-treated mice, but reported no significant difference in tumor size or histology, which may be related to the shorter TZD treatments used in this study (5 weeks as compared to 8 weeks in the first study). Similar findings were made in Apc+/1638N : Mlh1+/− double mutant mice. In these mice, one copy of the APC gene is truncated at amino acid position 1638 and one of the two alleles of the DNA repair enzyme Mlh1 is absent. In the double mutant mice, troglitazone treatment significantly increased the number of mice that developed large intestine tumors [58]. In contrast to these reports, another study used Apc+/1638N mice crossed with hemizygous PPARγ mice. Because homozygous deletion of PPARγ is embryonic-lethal, studies examining the dose effect of the gene employed either a hemizygous Pparγ−/− mouse strain or a conditional knockout strategy. No differences in survival, number of colonic tumors or β-catenin expression levels were observed between mice of Apc+/1638N : Pparγ+/− and Apc+/1638N : Pparγ−/+ littermates [57]. Therefore, in colon cancer induced by APC mutations, it appears that activation of PPARγ by TZDs promotes tumor formation, while reduction of PPARγ gene dosage has little effect on tumor formation.

In stark contrast to the APC genetic tumor models, carcinogen-generated colon cancer models seem to yield opposite results. In the study that evaluated PPARγ hapolinsufficiency in an Apc+/1638N background, the investigators also determined the effect of Pparγ+/− in azoxymethane-mediated colon cancer. Compared to the Pparγ+/− mice, a greater number of hapolinsufficient mice developed tumors in the colon. The tumor-bearing Pparγ+/− mice also had a greater number of tumors in them that led to significantly decreased survival. In another study, mice with
Table 5: PPARγ and agonists in animal models (differentially shaded according to methods of tumor induction).

| Cancer type     | Tumor induction                  | PPARγ activation (↑)/reduction (↓) | Tumor response                          | PPARγ’s effect | References |
|-----------------|----------------------------------|------------------------------------|-----------------------------------------|----------------|------------|
| Colon           | Apc+/Min                         | 1 Troglitazone, Rosiglitazone      | Increased incidence and size of tumor   | Promoting      | [55, 56]  |
| Colon           | Apc+/+1683N                      | 1 Pparγ/+                           | No response                             | No effect      | [57]       |
| Colon           | Apc+/+1683N ; Mlh1−/−           | 1 Troglitazone                     | Increased tumor incidence               | Promoting      | [58]       |
| Colon           | Azoxymethane                     | 1 Troglitazone, pioglitazone, or   | Decreased tumor incidence, number, and  | Suppressing    | [59]       |
| Colon           | Spontaneous                      | 1 Troglitazone (5 weeks)           | No response                             | No effect      | [56]       |
| Colon           | Spontaneous                      | 1 Troglitazone (6 months)          | Increased tumor incidence               | Promoting      | [58]       |
| Mammary glands  | Polyoma virus middle T antigen   | 1 Tissue specific constitutive     | Promoted tumor development              | Promoting      | [60]       |
| Mammary glands  | Polyoma virus middle T antigen   | Pparγ/+−                            | No response                             | No effect      | [60]       |
| Mammary glands  | MNU(a)                           | 1 GW7845                            | Decreased tumor incidence, number, and  | Suppressing    | [61]       |
| Mammary, ovarian, skin | DMBA(b)                 | Pparγ/+−                            | Increased tumor incidence and number, worse survival | Suppressing    | [62]       |
| Mammary glands  | Spontaneous                      | 1 Tissue-specific PPARγ deletion    | No response                             | No effect      | [63]       |
| Mammary glands  | Spontaneous                      | Pparγ/+−                            | No response                             | No effect      | [62]       |
| Prostate        | SV40 T antigen                   | Pparγ/+−                            | No response                             | No effect      | [64]       |
| Thyroid         | DN-TRβ(c)                        | Pparγ/+−                            | Increased metastases, shortened survival | Suppressing    | [65]       |
| Thyroid         | DN-TRβ                           | 1 Rosiglitazone                     | Reduced tumor growth, delayed progression | Suppressing    | [65]       |
| Gastric         | MNU                              | Pparγ/+−                            | Increased tumor incidence, shortened survival | Suppressing    | [66]       |
| Gastric         | MNU                              | 1 Troglitazone                      | Decreased tumor incidence               | Suppressing    | [66]       |
| Lung            | Urethan                          | 1 Tissue specific PPARγ overexpression | Decreased tumor incidence               | Suppressing    | [67]       |

(a) MNU, N-methyl-N-nitrosourea.
(b) DMBA, 7,12-dimethylbenzanthracene.
(c) DN-TRβ, dominant-negative mutant of thyroid hormone receptor β.

Un-shaded: Genetic tumor models
Light grey-shaded: Carcinogen-induced tumor models
Dark grey-shaded: Spontaneous tumor formation

Azoxy methane-mediated colon cancer were treated with troglitazone, pioglitazone, or rosiglitazone. This resulted in reduced incidence, number, and size of colorectal tumor [59]. Taken together, these data suggest that PPARγ suppress azoxymethane-induced colon carcinogenesis.

What would happen in normal mice? Spontaneous colon tumor development was evaluated in normal mice administered with troglitazone [58]. All nine mice fed with troglitazone developed tumors in the large intestine, in contrast to none of the 10 mice in the control group. An earlier study did not find any tumors in 17 troglitazone-fed normal mice, possibly due to the short duration of feeding (5 weeks in [56] versus 6 months in [58]).

4.2. Mammary gland tumors

The mammary gland tumor is another relatively well-studied tumor in animals. Similar to colon carcinogenesis, data on PPARγ’s role in mammary gland carcinogenesis suggest a wide range of effect depending on the tumor models (Tables 5 and 6). Some studies indicate no effect, while others suggest that it has a tumor promoting role, while others yet
suggest a tumor suppressing role. A murine genetic model supports a tumor-promoting role [60]. In this model, the mammary gland tumor is induced by mammary gland-specific expression of polyoma middle T antigen (MMTV-PyV). Mammary gland specific constitutive expression of PPARγ (MMTV-VpPPARγ) did not yield tumor development. However, when crossed with the MMTV-PyV mice, the double mutant progeny developed more mammary gland tumors sooner than MMTV-PyV mice. The increased tumor burden eventually led to shorter survival. Interestingly, hemizygosity of PPARγ in the MMTV-PyV background did not change the time course of tumor development. Exacerbation of tumor formation by PPARγ was ascribed to increased Wnt-β catenin signaling as demonstrated by zebrafish developmental models.

In contrast to this genetic model, chemically induced mammary gland tumors were inhibited by PPARγ agonists. Both TZDs and GW7845, a tyrosine analog, have been shown to exhibit antitumor effects. An early study using nitroso-methylurea (MNU) to induce mammary carcinogenesis showed that GW7845 reduced the incidence, number of tumors per animal, and average weight of tumor at autopsy.

| Cancer type | Tumor induction | PPARγ activation (↑/reduction ↓) | Tumor response | PPARγ’s effect | References |
|-------------|----------------|----------------------------------|----------------|----------------|------------|
| Colon       | APCMin/+       | ↑ Troglitazone, Rosiglitazone    | Increased incidence and size of tumor | Promoting   | [55, 56]   |
| Colon       | Apc1638N       | ↑ Pparγ/−                         | No response    | No effect     | [57]       |
| Colon       | Apc1638N ; Mlh1+/− | ↑ Troglitazone          | Increased tumor incidence | Promoting   | [58]       |
| Colon       | Azoxymethane   | ↑ Pparγ/−                        | Decreased tumor incidence, number, and size | Suppressing | [57]       |
| Colon       | Azoxymethane   | ↑ Troglitazone, pioglitazone, or rosiglitazone | No response | No effect     | [56]       |
| Colon       | Spontaneous    | ↑ Troglitazone (5 weeks)         | No response    | No effect     | [58]       |
| Mammary glands | Polyoma virus middle T antigen | ↑ Tissue specific constitutive activation of PPARγ | Promoted tumor development | Promoting   | [60]       |
| Mammary glands | Polyoma virus middle T antigen | ↑ Pparγ/− | No response | No effect | [60]       |
| Mammary glands | MNU(a)         | ↑ GW7845                         | Decreased tumor incidence, number, and total weight | Suppressing | [61]       |
| Mammary, ovarian, skin | DMBA(b)       | ↑ Pparγ/−                        | Increased tumor incidence and number, worse survival | Suppressing | [62]       |
| Mammary glands | Spontaneous    | ↑ Tissue-specific PPARγ deletion | No response | No effect | [63]       |
| Mammary glands | Spontaneous    | ↑ Pparγ/−                        | No response | No effect | [62]       |
| Prostate    | SV40 T antigen | ↑ Pparγ/−                        | No response | No effect | [64]       |
| Thyroid     | DN-TRβ(c)      | ↑ Rosiglitazone                  | Reduced tumor growth, delayed progression | Suppressing | [65]       |
| Gastric     | MNU            | ↑ Pparγ/−                        | Increased tumor incidence, shortened survival | Suppressing | [66]       |
| Gastric     | MNU            | ↑ Troglitazone                   | Decreased tumor incidence | Suppressing | [66]       |
| Lung        | Urethan        | ↑ Tissue-specific PPARγ1 overexpression | Decreased tumor incidence | Suppressing | [67]       |

(a)MNU, N-methyl-N-nitrosourea.
(b)DMBA, 7,12-dimethylbenzanthracene.
(c)DN-TRβ, dominant-negative mutant of thyroid hormone receptor β.

Un-shaded: Activation of PPARγ by pharmacological agonists
Light grey-shaded: Reduction of PPARγ gene dosage
Dark grey-shaded: Tissue specific PPARγ overexpression

Un-shaded: Activation of PPARγ by pharmacological agonists
Light grey-shaded: Reduction of PPARγ gene dosage
Dark grey-shaded: Tissue specific PPARγ overexpression

Exacerbation of tumor formation by PPARγ was ascribed to increased Wnt-β catenin signaling as demonstrated by zebrafish developmental models.

In contrast to this genetic model, chemically induced mammary gland tumors were inhibited by PPARγ agonists. Both TZDs and GW7845, a tyrosine analog, have been shown to exhibit antitumor effects. An early study using nitroso-methylurea (MNU) to induce mammary carcinogenesis showed that GW7845 reduced the incidence, number of tumors per animal, and average weight of tumor at autopsy.

Un-shaded: Activation of PPARγ by pharmacological agonists
Light grey-shaded: Reduction of PPARγ gene dosage
Dark grey-shaded: Tissue specific PPARγ overexpression

Exacerbation of tumor formation by PPARγ was ascribed to increased Wnt-β catenin signaling as demonstrated by zebrafish developmental models.

In contrast to this genetic model, chemically induced mammary gland tumors were inhibited by PPARγ agonists. Both TZDs and GW7845, a tyrosine analog, have been shown to exhibit antitumor effects. An early study using nitroso-methylurea (MNU) to induce mammary carcinogenesis showed that GW7845 reduced the incidence, number of tumors per animal, and average weight of tumor at autopsy.

Table 6: PPARγ and agonists in animal models (differentially shaded according to methods of PPARγ manipulation).
following a two-month administration of the drug to rats [61]. In 7,12-dimethylbenzanthracene (DMBA)-mediated mouse carcigenesis model, the animals develop multiple types of tumor, including mammary ductal papilloma and adenocarcinoma. Incidence of mammary gland tumor was significantly higher in Pparγ−/− mice than in Pparγ+/+ mice. The hemizygous mice also had increased number of tumors and a lower survival rate [62].

Spontaneous tumor formation was also examined in Pparγ+/− mice. Dose reduction of PPARγ does not make animals prone to increased carcinogenesis [62]. In concordance with this finding, the specific deletion of PPARγ in mouse mammary epithelia failed to induce mammary tumors in 20 mice observed for 12 months [63].

4.3. Other cancers

In a murine prostate cancer model, generated using tissue-specific SV40 T antigen, reduced Pparγ+/− had no effects on tumor incidence, latency, size, histopathology, or disease progression [64]. However, in a murine follicular thyroid cancer model containing a dominant-negative mutant form of thyroid hormone receptor β (TRβPV/PV), loss of one PPARγ allele led to increased weight of tumor-bearing thyroid gland, increased lung metastasis, and shortened survival. In addition, rosiglitazone treatment of TRβPV/PV mice reduced thyroid weight, and tumor progression [65], suggesting a tumor-suppressing role for PPARγ. Lastly, in gastric carcinoma, induced with MNU, PPARγ haploinsufficient mice had increased tumor incidence and shorter survival. Troglitazone treatment significantly reduced tumor incidence in mice with wild-type PPARγ background [66].

In summary, results from animal studies regarding the role of PPARγ are conflicting and difficult to assess. For the purpose of clarification, we attempted to analyze the published data according to the cancer types, tumor induction models, PPARγ activation/reduction methods, and tumor characteristics (Tables 5 and 6). Our extensive analysis revealed no clear pattern. However, some trends have been noted: (1) in multiple types of carcinogen-induced tumor (Table 5, light grey shaded rows), PPARγ seems to have a tumor-suppressing function. This appears to be independent of how PPARγ is activated or reduced, whereas in genetic tumor models (Table 5, un-shaded rows), the receptor exhibited all possible different effects. As to spontaneous tumors (Table 5, dark grey shaded rows), long-term use of troglitazone increased tumor formation, whereas PPARγ reduction had no effect; (2) a reduction of PPARγ dose by itself (Table 6, light grey shaded rows) is insufficient to induce spontaneous tumor formation, but in existing tumors, it either exacerbates tumor formation or have no effect at all; (3) TZDs (Table 6, un-shaded rows), in most cases, inhibits tumor formation with a rare exception of Apc+/Min mice.

The activity of the Wnt/β-catenin signaling pathway might account for these seemingly discrepant results, as tumor models generated by APC mutation or polyoma middle T antigen all involve overly active Wnt/β-catenin signaling. TZDs are shown to induce β-catenin in colon [55]. Paradoxically, reduction of PPARγ (Pparγ−/−) also increases β-catenin expression in colon [57]. The appropriate activation of PPARγ signaling might also be important. Ligand-independent constitutive activation of PPARγ is involved in the development of mammary gland tumors [60] as well as in the action of PAX8-PPARγ in follicular thyroid carcinoma [29].

5. Clinical Trials of TZDs in Human Malignancies

As discussed above, TZDs have been shown in many preclinical studies to possess antitumor effects that have prompted several early-phase clinical studies to evaluate their efficacies in various types of cancers. In this review, we analyze these studies both in terms of clinical responses and biological responses, focusing on recently published studies that include more than 10 patients (Table 7).

A phase II clinical trial of rosiglitazone in 12 patients with liposarcoma was recently conducted. Eight of 12 patients were fully evaluated for up to 16 months. As to clinical response, all patients progressed while on treatment with a mean time-to-progression of 5.5 months. Histological appearance of repeated biopsy materials did not show any signs of tumor differentiation. In one of the 8 patients, PPARγ and fatty acid binding protein (FABP) were induced after 12-week rosiglitazone therapy, but disease in this patient progressed similarly to the others [68]. Ten patients with thyroid cancers were treated with rosiglitazone. Among them, 4 had partial response, 2 had stable disease, and the remaining 4 progressed. No correlation was found between the clinical response and levels of PPARγ mRNA and protein in these patients. PAX8-PPARγ status was not assessed [69]. An early study evaluated efficacy of troglitazone in 25 patients with metastatic colorectal carcinoma. All 25 patients progressed with a median time-to-progression of 1.6 months and a median survival time of 3.9 months [70].

In breast cancer, data from two human trials have been published. An early trial on 22 women with refractory breast cancer showed no objective response to troglitazone in 18 of the 21 evaluable patients at 8 weeks after treatment. The therapy was terminated in 16 patients due to progression of their tumors. At 8 weeks, only three patients had stable disease. All patients were evaluated for serum tumor markers, CEA and CA27.29, which showed increased levels within 8 weeks of treatment. Expression of PPARγ was not determined in the study [71]. A short-term pilot trial of rosiglitazone in 38 women with early stage breast cancer was conducted. Clinical response was not assessed in this short-term (<6 week) study. Biological response, as assessed by Ki-67 staining on biopsy tissues before and after treatment, was not detected in treated patients, either. Decreased insulin levels and increased insulin sensitivity were noted in these patients, suggesting that the rosiglitazone did affect metabolism as expected [72].

An early phase II trial of troglitazone in 41 patients with metastatic prostate cancer showed a decrease in levels of prostate-specific antigen (PSA) in 20% of patients enrolled
in the study. Prolonged stabilization of PSA was seen in 39% of patients [73]. However, these encouraging results were not reproduced in a large double-blind, randomized, placebo-controlled trial of rosiglitazone in 106 patients with recurrent prostate cancer [74]. The time-to-disease-progression was not significantly different between the rosiglitazone and placebo groups. Moreover, the PSA doubling time, a predictor of clinical recurrence, was also not prolonged by the treatment.

Taken together, TZDs appear to show little benefit, both in terms of clinical response and biological response, in treating various types of human cancers despite promising results from preclinical animal studies. It is worth noting that most of the studies use low doses of TZDs which are sufficient to activate PPARγ and control diabetes. It remains possible that higher doses, even via receptor-independent pathways, would be beneficial for cancer patients. However, one should keep in mind that TZDs are not a class of drugs without dose-limiting toxicities. Troglitazone was withdrawn from the market by the FDA in 2002 due to liver toxicity. Most recently, increased cardiovascular risk has been associated with rosiglitazone in the diabetic patient population [75, 76] which has prompted the FDA to issue label warnings.

### 6.TZDs AS CHEMOPREVENTIVE AGENTS IN EPIDEMIOLOGY STUDIES

The clinical trials discussed above suggest that TZDs have questionable efficacy as chemotherapeutic agents in patients who already have cancers. Do they have the potential to act as chemopreventive agents? Recently, a large epidemiologic study, involving a population of 87,678 veteran men with diabetes, attempted to answer that question [77]. In this retrospective study, incidence of lung, prostate, and colon cancer in TZD users was compared to incidence in non-TZD users and risk of cancer development was analyzed. Only patients who obtained a cancer diagnosis after the date of TZD initiation were included. TZD usage significantly reduced risk of lung cancer by 33%. It also reduced risk of colon and prostate cancer, though without statistical significance. Interestingly, although the risk of prostate cancer is not significantly influenced by TZDs in the entire population, when examining distinct populations, TZDs are associated with an increased incidence of prostate cancer in both Caucasians and African Americans. These data suggest that the overall reduced risk is accounted for by the non-Caucasian, non-African Americans populations in the study. These data suggest that TZDs may be beneficial for reducing certain cancers in certain populations. Specific molecular abnormalities in specific cancers and the genetic background of different populations may account for these apparently different results.

Although this study was quite strong, we suggest the following for future investigations: (1) separate TZD-users into those using rosiglitazone and those using pioglitazone. In the cardiovascular risk studies, it was shown that rosiglitazone increases the risk while pioglitazone decreases the risk [78]. (2) Evaluate the impact of the duration of TZD exposure on risk of cancer development. (3) Determine the influence of TZDs on the behavior of existing cancers.

### 7. CONCLUSIONS

In this article, we reviewed literature on the roles of PPARγ in cancer with an emphasis on those that suggest a proneoplastic function for the receptor. PPARγ, unlike MYC, RAS, or p53, is neither a strong tumor promoter nor a tumor suppressor. However, it may function as a “conditional tumor promoter” or a “conditional tumor suppressor” that modulates the tumorigenic process depending upon cellular conditions, tumor types, or genetic background of an animal strain or human individuals. TZDs, as a class of pharmacological agent, may have receptor-independent antineoplastic effects, especially at doses higher than diabetic doses or after long-term use and accumulation. It remains possible that their antitumor activities would be enhanced when in combination with other drugs. Further investigation is needed to address that possibility. To help clarify the roles of PPARγ in cancer, future large epidemiological studies of diabetic populations with concurrent cancers would be helpful. In addition, investigations relating PPARγ activities to the clinical outcomes of cancer patients would also be informative.
ACKNOWLEDGMENTS

The authors would like to dedicate this article to the memory of Dr. Judah Folkman. They thank Jonathan S. Kui for critical reading of the manuscript.

REFERENCES

[1] J. M. Lehmann, L. B. Moore, T. A. Smith-Oliver, W. O. Wilkison, T. M. Willson, and S. A. Kliewer, “An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ),” *Journal of Biological Chemistry*, vol. 270, no. 22, pp. 12953–12956, 1995.

[2] A. Rossi, P. Kapahi, G. Natoli, et al., “Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase,” *Nature*, vol. 403, no. 6765, pp. 103–108, 2000.

[3] K. M. Fuenzalida, M. C. Aguilera, D. G. Piderit, et al., “Peroxisome proliferator-activated receptor γ is a novel target of the nerve growth factor signaling pathway in PC12 cells,” *Journal of Biological Chemistry*, vol. 280, no. 10, pp. 9604–9609, 2005.

[4] C. Fionda, F. Nappi, M. Piccoli, L. Frati, et al., “15-deoxy-Δ12,14-prostaglandin J2 negatively regulates rankl gene expression in activated T lymphocytes: role of NF-κB and early growth response transcription factors,” *Journal of Immunology*, vol. 178, no. 7, pp. 4039–4050, 2007.

[5] T. M. Willson, J. E. Cobb, D. J. Cowan, et al., “The structure-activity relationship between peroxisome proliferator-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones,” *Journal of Medicinal Chemistry*, vol. 39, no. 3, pp. 665–668, 1996.

[6] T. M. Willson, P. J. Brown, D. D. Sternbach, and B. R. Henke, “The PPARs: from orphan receptors to drug discovery,” *Journal of Medicinal Chemistry*, vol. 43, no. 4, pp. 527–550, 2000.

[7] S. A. Kliewer, J. M. Lenhard, T. M. Willson, I. Patel, D. C. Morris, and J. M. Lehmann, “A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation,” *Cell*, vol. 83, no. 5, pp. 813–819, 1995.

[8] E. L. Harrington and S. R. Cox, “Determination of ciglitazone in dog plasma by reversed-phase high-performance liquid chromatography,” *Journal of Pharmaceutical and Biomedical Analysis*, vol. 3, no. 5, pp. 483–487, 1985.

[9] D. A. Eckland and M. Danhof, “Clinical pharmacokinetics of pioglitazone,” *Experimental & Clinical Endocrinology and Diabetes*, vol. 108, supplement 2, pp. S234–S242, 2000.

[10] M. A. Young, S. Lettis, and R. Eastmond, “Improvement in the gastrointestinal absorption of troglitazone when taken with, or shortly after, food;,” *British Journal of Clinical Pharmacology*, vol. 45, no. 1, pp. 31–35, 1998.

[11] A. Mouihate, L. Boissé, and Q. J. Pittman, “A novel antipyrretic action of 15-deoxy-Δ12,14-prostaglandin J1 in the rat brain,” *Journal of Neuroscience*, vol. 24, no. 6, pp. 1312–1318, 2004.

[12] L. C. Bell-Parikh, T. Ide, J. A. Lawson, P. McNamara, M. Reilly, and G. A. FitzGerald, “Biosynthesis of 15-deoxy-Δ12,14-PGJ2 and the ligand of PPARγ,” *Journal of Clinical Investigation*, vol. 112, no. 6, pp. 945–955, 2003.

[13] Y. Segawa, R. Yoshimura, T. Hase, et al., “Expression of peroxisome proliferator-activated receptor (PPAR) in human prostate cancer,” *Prostate*, vol. 51, no. 2, pp. 108–116, 2002.

[14] K. Inoue, Y. Kawahito, Y. Tsubouchi, et al., “Expression of peroxisome proliferator-activated receptor γ in renal cell carcinoma and growth inhibition by its agonists,” *Biochemical and Biophysical Research Communications*, vol. 287, no. 3, pp. 727–732, 2001.

[15] V. G. Keshamouni, R. C. Reddy, D. A. Arenberg, et al., “Peroxisome proliferator-activated receptor-γ activation inhibits tumor progression in non-small-cell lung cancer,” *Oncogene*, vol. 23, no. 1, pp. 100–108, 2004.

[16] K. L. Schaefer, K. Wada, H. Takahashi, et al., “Peroxisome proliferator-activated receptor γ inhibition prevents adhesion to the extracellular matrix and induces anoikis in hepatocellular carcinoma cells,” *Cancer Research*, vol. 65, no. 6, pp. 2251–2259, 2005.

[17] T. Masuda, K. Wada, A. Nakajima, et al., “Critical role of peroxisome proliferator-activated receptor γ on anoikis and invasion of squamous cell carcinoma,” *Clinical Cancer Research*, vol. 11, no. 11, pp. 4012–4021, 2005.

[18] E. Elstner, C. Müller, K. Koshizuka, et al., “Ligands for peroxisome proliferator-activated receptor and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 95, no. 15, pp. 8806–8811, 1998.

[19] K. Ohta, T. Endo, K. Haraguchi, J. M. Hershman, and T. Onaya, “Ligands for peroxisome proliferator-activated receptor γ inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells,” *Journal of Clinical Endocrinology & Metabolism*, vol. 86, no. 5, pp. 2170–2177, 2001.

[20] E. Mueller, P. Sarraf, P. Tontonoz, et al., “Terminal differentiation of human breast cancer through PPARγ,” *Molecular Cell*, vol. 1, no. 3, pp. 465–470, 1998.

[21] G. Y. Zhang, N. Ahmed, C. Riley, et al., “Enhanced expression of peroxisome proliferator-activated receptor γ in epithelial ovarian carcinoma,” *British Journal of Cancer*, vol. 92, no. 1, pp. 113–119, 2005.

[22] R. Yoshimura, M. Matsuyama, Y. Segawa, et al., “Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists,” *International Journal of Cancer*, vol. 104, no. 5, pp. 597–602, 2003.

[23] G. Kristiansen, J. Jacob, A.-C. Buckendahl, et al., “Peroxisome proliferator-activated receptor γ is highly expressed in pancreatic cancer and is associated with shorter overall survival times,” *Clinical Cancer Research*, vol. 12, no. 21, pp. 6444–6451, 2006.

[24] P. Sarraf, E. Mueller, D. Jones, et al., “Differentiation and reversal of malignant changes in colon cancer through PPARγ,” *Nature Medicine*, vol. 4, no. 9, pp. 1046–1052, 1998.

[25] H. Sato, S. Ishihara, K. Kawashima, et al., “Expression of peroxisome proliferator-activated receptor (PPARγ) in gastric cancer and inhibitory effects of PPARγ agonists,” *British Journal of Cancer*, vol. 83, no. 10, pp. 1394–1400, 2000.

[26] P. Tontonoz, S. Singer, B. M. Forman, et al., “Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor γ and the retinoid X receptor,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 94, no. 1, pp. 237–241, 1997.

[27] M. J. Betz, I. Shapiro, M. Fassnacht, et al., “Peroxisome proliferator-activated receptor-γ agonists suppress adrenocortical tumor cell proliferation and induce differentiation,” *Journal of Clinical Endocrinology & Metabolism*, vol. 90, no. 7, pp. 3886–3896, 2005.
carcinogenesis in \( Ap^{	ext{H2O2}}/ Mlh1^{+/−} \) double mutant mice," *International Journal of Cancer*, vol. 116, no. 4, pp. 495–499, 2005.

[59] E. Osawa, A. Nakajima, K. Wada, et al., “Peroxisome proliferator-activated receptor \( \gamma \) ligands suppress colon carcinogenesis induced by azoxymethane in mice," *Gastroenterology*, vol. 124, no. 2, pp. 361–367, 2003.

[60] E. Saez, J. Rosenfeld, A. Livolsi, et al., “PPAR \( \gamma \) signaling exacerbates mammary gland tumor development," *Genes & Development*, vol. 18, no. 5, pp. 528–540, 2004.

[61] N. Suh, Y. Wang, C. R. Williams, et al., “A new ligand for the peroxisome proliferator-activated receptor-\( \gamma \) (PPAR-\( \gamma \)), GW7845, inhibits rat mammary carcinogenesis," *Cancer Research*, vol. 59, no. 22, pp. 5671–5673, 1999.

[62] C. J. Nicol, M. Yoon, J. M. Ward, et al., “PPAR\( \gamma \) influences susceptibility to DMBA-induced mammary, ovarian and skin carcinogenesis," *Carcinogenesis*, vol. 25, no. 9, pp. 1747–1755, 2004.

[63] Y. Cui, K. Miyoshi, E. Claudio, et al., “Loss of the peroxisome proliferation-activated receptor \( \gamma \) (PPAR\( \gamma \)) does not affect mammary development and propensity for tumor formation but leads to reduced fertility," *Journal of Biological Chemistry*, vol. 277, no. 20, pp. 17830–17835, 2002.

[64] E. Saez, P. Olson, and R. M. Evans, “Genetic deficiency in \( Pparg \) does not alter development of experimental prostate cancer," *Nature Medicine*, vol. 9, no. 10, pp. 1265–1266, 2003.

[65] Y. Kato, H. Ying, L. Zhao, et al., “PPAR\( \gamma \) insufficiency promotes follicular thyroid carcinogenesis via activation of the nuclear factor-xB signaling pathway," *Oncogene*, vol. 25, no. 19, pp. 2736–2747, 2006.

[66] J. Lu, K. Imamura, S. Nomura, et al., “Chemopreventive effect of peroxisome proliferator-activated receptor \( \gamma \) on gastric carcinogenesis in mice," *Cancer Research*, vol. 65, no. 11, pp. 4769–4774, 2005.

[67] Y. Bren-Mattison, A. M. Meyer, V. Van Putten, et al., “Antitumorigenic effects of peroxisome proliferator-activated receptor-\( \gamma \) in non-small-cell lung cancer cells are mediated by suppression of cyclooxygenase-2 via inhibition of nuclear factor-xB," *Molecular Pharmacology*, vol. 73, no. 3, pp. 709–717, 2008.

[68] G. Debrock, V. Vanhentenrijk, R. Sciot, M. Debiec-Rychter, R. Oyen, and A. Van Oosterom, “A phase II trial with rosiglitazone in liposarcoma patients," *British Journal of Cancer*, vol. 89, no. 8, pp. 1409–1412, 2003.

[69] E. Kebebew, M. Peng, E. Reiff, et al., “A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radiiodine-negative differentiated thyroid cancer," *Surgery*, vol. 140, no. 6, pp. 960–967, 2006.

[70] M. H. Kulke, G. D. Demetri, N. E. Sharpless, et al., “A phase II study of troglitazone, an activator of the PPAR\( \gamma \) receptor, in patients with chemotherapy-resistant metastatic colorectal cancer," *Cancer Journal*, vol. 8, no. 5, pp. 395–399, 2002.

[71] H. J. Burstein, G. D. Demetri, E. Mueller, P. Sarraf, B. M. Spiegelman, and E. P. Winer, “Use of the peroxisome proliferator-activated receptor (PPAR) \( \gamma \) ligand troglitazone as treatment for refractory breast cancer: a phase II study," *Breast Cancer Research and Treatment*, vol. 79, no. 3, pp. 391–397, 2003.

[72] L. D. Yee, N. Williams, P. Wen, et al., “Pilot study of rosiglitazone therapy in women with breast cancer: effects of short-term therapy on tumor tissue and serum markers," *Clinical Cancer Research*, vol. 13, no. 1, pp. 246–252, 2007.

[73] E. Mueller, M. Smith, P. Sarraf, et al., “Effects of ligand activation of peroxisome proliferator-activated receptor \( \gamma \) in human prostate cancer," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 97, no. 20, pp. 10990–10995, 2000.

[74] M. R. Smith, J. Manola, D. S. Kaufman, et al., “Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy," *Cancer*, vol. 101, no. 7, pp. 1569–1574, 2004.

[75] S. E. Nissen and K. Wolski, “Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes," *The New England Journal of Medicine*, vol. 356, no. 24, pp. 2457–2471, 2007.

[76] P. D. Home, S. J. Pocock, H. Beck-Nielsen, et al., “Rosiglitazone evaluated for cardiovascular outcomes—an interim analysis," *The New England Journal of Medicine*, vol. 357, no. 1, pp. 28–38, 2007.

[77] R. Govindarajan, L. Ratnasinghe, D. L. Simmons, et al., “Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes," *Journal of Clinical Oncology*, vol. 25, no. 12, pp. 1476–1481, 2007.

[78] C. J. Rosen, “The rosiglitazone story—lessons from an FDA advisory committee meeting," *The New England Journal of Medicine*, vol. 357, no. 9, pp. 844–846, 2007.